Microtubule Inhibitor drugs compared
Compare all 4 Microtubule Inhibitor drugs side by side, used for conditions such as breast neoplasms, carcinoma, non-small-cell lung, head and neck neoplasms. They share one FDA-defined mechanism but differ in approved uses, prescription status, brand-vs-generic options, price, and FDA recall-safety record — which our independent rating scores.
Full ranking · 4 drugs
- 170/100
taxotere
Docetaxel
- 2New
docivyx
Docetaxel
- 3New
eribulin mesylate
Eribulin Mesylate
- 4New
halaven
Eribulin Mesylate
Frequently asked questions
What is the Microtubule Inhibitor drug class?
Microtubule Inhibitor is an FDA Established Pharmacologic Class (EPC) — a group of drugs that share a mechanism of action. pharmaranks lists 4 Microtubule Inhibitor products, each independently rated.
Are all Microtubule Inhibitor drugs the same?
No. Microtubule Inhibitor drugs share the same core mechanism — that is why they sit in one FDA class — but they differ in their approved uses, available forms, whether they are prescription or over-the-counter, brand-vs-generic options and price, and their FDA recall-safety record.
What conditions do Microtubule Inhibitor drugs treat?
Per NIH RxClass drug-classification data, Microtubule Inhibitor drugs are used for conditions including breast neoplasms, carcinoma, non-small-cell lung, head and neck neoplasms, melanoma, ovarian neoplasms, pancreatic neoplasms.
Sources: the Microtubule Inhibitor class definition and its member drugs come from the U.S. NLM RxClass (Established Pharmacologic Class). Ratings are pharmaranks’ independent FDA recall-safety analysis.